Nasdaq

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits ...
Nasdaq

Cocrystal Pharma Announces Enrollment Extension in Phase 2a Study of Influenza Treatment CC-42344 Due to Low Infection Rates

Data indicates a favorable safety and tolerability profile for CC-42344, with no serious adverse events or drug-related discontinuations reported. Extension of enrollment in the Phase 2a study allows ...
Seeking Alpha

Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam ...
Seeking Alpha

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent ...